Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,212.00
(
1.70%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
96.72
(
1.80%
)
Bitcoin
78,571.67
(
2.94%
)
News Focus
News Focus
Post# of 257437
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 248690

Friday, 10/13/2023 9:11:39 PM

Friday, October 13, 2023 9:11:39 PM

Post# of 257437
HRMY—(-30%)—misses primary endpoint_in phase-3 idiopathic hypersomnia trial:

https://finance.yahoo.com/news/harmony-biosciences-announces-topline-data-120000326.html

A positive trend favoring pitolisant was observed during the 4-week double-blind randomized withdrawal period, however no statistically significant difference was observed between pitolisant and placebo groups on ESS, the primary endpoint.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today